PMID- 11943080
OWN - NLM
STAT- MEDLINE
DCOM- 20020509
LR  - 20170214
IS  - 0023-6772 (Print)
IS  - 0023-6772 (Linking)
VI  - 36
IP  - 2
DP  - 2002 Apr
TI  - Failure of liver cirrhosis induction by thioacetamide in Nagase analbuminaemic 
      rats.
PG  - 158-64
AB  - Repeated administration of thioacetamide (TA), either intraperitoneally or in 
      drinking water, produced liver cirrhosis in normal Sprague-Dawley rats (SDR) with 
      significant histological alterations similar to those observed in human 
      cirrhosis. In the present study, we evaluated the ability of TA to induce liver 
      cirrhosis in mutant Nagase analbuminaemic SDR. Thioacetamide was administered 
      either intraperitoneally up to 4 months or in drinking water up to 6 months to 
      normal and to Nagase analbuminaemic SDR. Nagase analbuminaemic rats (NAR) were 
      also administered TA in drinking water up to 10 months. Liver cirrhosis 
      development was determined by macroscopic and microscopic analysis. In contrast 
      to normal SDR, no histological characteristics of cirrhosis could be observed in 
      NAR submitted to a 4 or 6 months treatment with TA. Such failure to induce 
      cirrhosis in Nagase rats was confirmed even after prolonged TA administration in 
      drinking water for up to 10 months. In contrast, fibrosis and cholangiolar 
      proliferation occurred in the 10-month TA-treated analbuminaemic rats, suggesting 
      that the mechanisms involved in cirrhosis induction are different from those 
      involved in fibrosis development and carcinogenesis. It is unlikely that the 
      protective effect against TA-induced cirrhosis observed in analbuminaemic rats is 
      related to the absence of albumin in this rat strain, since a co-administration 
      of TA with albumin in analbuminaemic rats did not restore the potential for TA to 
      induce cirrhosis in this rat strain. In conclusion, the fact that induction of 
      cirrhosis by TA is prevented in the inherently hyperlipidaemic and 
      hypercholesterolaemic analbuminaemic rats could be considered for potential 
      application in the treatment of clinical cirrhosis.
FAU - David, Pascale
AU  - David P
AD  - Laboratoire de Chirurgie Experimentale, Fondation Transplantation, 5, avenue 
      Moliere, 67200 Strasbourg, France.
FAU - Alexandre, Eliane
AU  - Alexandre E
FAU - Chenard-Neu, Marie-Pierre
AU  - Chenard-Neu MP
FAU - Wolf, Philippe
AU  - Wolf P
FAU - Jaeck, Daniel
AU  - Jaeck D
FAU - Richert, Lysiane
AU  - Richert L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lab Anim
JT  - Laboratory animals
JID - 0112725
RN  - 0 (Serum Albumin)
RN  - 075T165X8M (Thioacetamide)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Bile Ducts, Intrahepatic/drug effects/pathology
MH  - Cell Division/drug effects
MH  - Cholangitis/chemically induced/pathology
MH  - Disease Models, Animal
MH  - Hypercholesterolemia/genetics
MH  - Injections, Intraperitoneal
MH  - Liver Cirrhosis/*chemically induced/genetics/pathology/prevention & control
MH  - Rats
MH  - Rats, Mutant Strains
MH  - Rats, Sprague-Dawley
MH  - Serum Albumin/*deficiency/genetics
MH  - Thioacetamide/administration & dosage/*toxicity
MH  - Water Supply
EDAT- 2002/04/12 10:00
MHDA- 2002/05/10 10:01
CRDT- 2002/04/12 10:00
PHST- 2002/04/12 10:00 [pubmed]
PHST- 2002/05/10 10:01 [medline]
PHST- 2002/04/12 10:00 [entrez]
AID - 10.1258/0023677021912442 [doi]
PST - ppublish
SO  - Lab Anim. 2002 Apr;36(2):158-64. doi: 10.1258/0023677021912442.